The extent of the collateral circulation influences the postprandial increase in portal pressure in patients with cirrhosis

Gut

Volumn 56, Issue 2, 2007, Pages 259-264

  Albillos, Agustín ^a,b   Bañares, Rafael ^c   González, Mónica ^b   Catalina, Maria Vega ^c   Pastor, Oscar ^b   Gonzalez, Rosario ^b   Ripoll, Cristina ^c   Bosch, Jaime ^d  

^a UNIVERSITY OF ALCALÁ   (Spain)

^b HOSPITAL RAMÓN Y CAJAL   (Spain)

^c HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^d UNIVERSITY OF BARCELONA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; NITRIC OXIDE;

ADULT; AGED; ARTICLE; AZYGOS VEIN; COLLATERAL CIRCULATION; CONTROLLED STUDY; HUMAN; LIVER BLOOD FLOW; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; PORTAL VEIN BLOOD PRESSURE; POSTPRANDIAL STATE; PRIORITY JOURNAL; VARICOSIS;

ADULT; AGED; AZYGOS VEIN; COLLATERAL CIRCULATION; EATING; FEMALE; HEPATIC VEINS; HUMANS; HYPEREMIA; LIVER CIRCULATION; LIVER CIRRHOSIS; MALE; MIDDLE AGED; NITROGEN OXIDES; PORTAL PRESSURE; POSTPRANDIAL PERIOD;

EID: 33847008087     PISSN: 00175749     EISSN: None     Source Type: Journal    
DOI: 10.1136/gut.2006.095240     Document Type: Article

References (33)

1. Moneta GL, Taylor DC, Helton WS, et al. Duplex ultrasound measurement of postprandial intestinal blood flow: effect of meal composition. Gastroenterology 1988;95:1294-301.
2. Sabba C, Ferraioli G, Genecin P, et al. Evaluation of postprandial hyperemia in superior mesenteric artery and portal vein in healthy and cirrhotic humans: an operator-blind echo-Doppler study. Hepatology 1991;13:714-18.
3. Gupta TK, Toruner M, Chung MK, et al. Endothelial dysfunction and decreased production of nitric oxide in the intrahepatic microcirculation of cirrhotic rats. Hepatology 1998;28:926-31.
4. Loureiro-Silva MR, Cadelina GW, Iwakiri Y, et al. A liver-specific nitric oxide donor improves the intra-hepatic vascular response to both portal blood flow increase and methoxamine in cirrhotic rats. J Hepatol 2003;39:940-6.
5. Lee SS, Hadengue A, Moreau R, et al. Postprandial hemodynamic responses in patients with cirrhosis. Hepatology 1988;8:647-51.
6. Gaiani S, Bolondi L, Li Bassi S, et al. Effect of meal on portal hemodynamics in healthy humans and in patients with chronic liver disease. Hepatology 1989;9:815-19.
7. Bendtsen F, Simonsen L, Henriksen JH. Effect on hemodynamics of a liquid meal alone and in combination with propranolol in cirrhosis. Gastroenterology 1992;102:1017-23.
8. Albillos A, Rossi I, Iborra J, et al. Octreotide prevents postprandial splanchnic hyperemia in patients with portal hypertension. J Hepatol 1994;21:88-94.
9. McCormick PA, Biagini MR, Dick R, et al. Octreotide inhibits the meal-induced increases in the portal venous pressure of cirrhotic patients with portal hypertension: a double-blind, placebo-controlled study. Hepatology 1992;16:1180-6.
10. Vorobioff JD, Gamen M, Kravetz D, et al. Effects of long-term propranolol and octreotide on postprandial hemodynamics in cirrhosis: a randomized, controlled trial. Gastroenterology 2002;122:916-22.
11. Bellis L, Berzigotti A, Abraldes JG, et al. Low doses of isosorbide mononitrate attenuate the postprandial increase in portal pressure in patients with cirrhosis. Hepatology 2003;37:378-84.
12. Shah V, Toruner M, Haddad F, et al. Impaired endothelial nitric oxide synthase activity associated with enhanced caveolin binding in experimental cirrhosis in the rat. Gastroenterology 1999;117:1222- 8.
13. Kroeger RJ, Groszmann RJ. Increased portal venous resistance hinders portal pressure reduction during the administration of beta-adrenergic blocking agents in a portal hypertensive model. Hepatology 1985;5:97-101.
14. Bosch J, Groszmann RJ. Measurement of azygos venous blood flow by a continuous thermal dilution technique: an index of blood flow through gastroesophageal collaterals in cirrhosis. Hepatology 1984;4:424-9.
15. Sakurabayashi S, Koh KC, Chen L, et al. Octreotide ameliorates the increase in collateral blood flow during postprandial hyperemia in portal hypertensive rats. J Hepatol 2002;36:507-12.
16. Polio J, Groszmann RJ. Hemodynamic factors involved in the development and rupture of esophageal varices: a pathophysiologic approach to treatment. Semin Liver Dis 1986;6:318-31.
17. de Franchis R. Updating consensus in portal hypertension: report of the Baveno III Consensus Workshop on definitions, methodology and therapeutic strategies in portal hypertension. J Hepatol 2000;33:846-52.
18. Bosch J, Masti R, Kravetz D, et al. Effects of propranolol on azygos venous blood flow and hepatic and systemic hemodynamics in cirrhosis. Hepatology 1984;4:1200-5.
19. Bosch J, Mastai R, Kravetz D, et al. Measurement of azygos venous blood flow in the evaluation of portal hypertension in patients with cirrhosis. Clinical and haemodynamic correlations in 100 patients. J Hepatol 1985;1:125-39.
20. Albillos A, Garcia-Pagan JC, Iborra J, et al. Propranolol plus prazosin compared with propranolol plus isosorbide-5-mononitrate in the treatment of portal hypertension. Gastroenterology 1998;115:116- 23.
21. Zafra C, Abraldes JG, Turnes J, et al. Simvastatin enhances hepatic nitric oxide production and decreases the hepatic vascular tone in patients with cirrhosis. Gastroenterology 2004;126:749-55.
22. Mosca P, Lee FY, Kaumann AJ, et al. Pharmacology of portal-systemic collaterals in portal hypertensive rats: role of endothelium. Am J Physiol 1992;263(Pt 1):G544-50.
23. Lee FY, Colombato LA, Albillos A, et al. Administration of N omega-nitro-L-arginine ameliorates portal-systemic shunting in portal-hypertensive rats. Gastroenterology 1993;105:1464-70.
24. Chan CC, Wang SS, Lee FY, et al. Endothelin-1 induces vasoconstriction on portal-systemic collaterals of portal hypertensive rats. Hepatology 2001;33:816-20.
25. Ludwig D, Schwarting K, Korbel CM, et al. The postprandial portal flow is related to the severity of portal hypertension and liver cirrhosis. J Hepatol 1998;28:631-8.
26. Siringo S, Piscaglia F, Zironi G, et al. Influence of esophageal varices and spontaneous portal-systemic shunts on postprandial splanchnic hemodynamics. Am J Gastroenterol 2001;96:550-6.
27. Fiorucci S, Antonelli E, Brancaleone V, et al. NCX-1000, a nitric oxide-releasing derivative of ursodeoxycholic acid, ameliorates portal hypertension and lowers norepinephrine-induced intrahepatic resistance in the isolated and perfused rat liver. J Hepatol 2003;39:932-9.
28. Garcia-Tsao G, Grace ND, Groszmann RJ, et al. Short-term effects of propranolol on portal venous pressure. Hepatology 1986;6:101-6.
29. Groszmann RJ, Garcia-Tsao G, Bosch J, et al. Beta-blockers to prevent gastroesophageal varices in patients with cirrhosis. N Engl J Med 2005;353:2254-61.
30. Vorobioff J, Groszmann RJ, Picabea E, et al. Prognostic value of hepatic venous pressure gradient measurements in alcoholic cirrhosis: a 10-year prospective study. Gastroenterology 1996;111:701-9.
31. Abraldes J, Iwakiri Y, Loureiro-Silva M, et al. Mild increases in portal pressure upregulate VEGF and eNOS in the intestinal microcirculatory bed leading to vasodilatation and the hyperdynamic circulation. J Hepatol 2005;42(Suppl 2):27-8A.
32. Fernandez M, Vizzutti F, Garcia-Pagan JC, et al. Anti-VEGF receptor-2 monoclonal antibody prevents portal-systemic collateral vessel formation in portal hypertensive mice. Gastroenterology 2004;126:886-94.
33. Escorsell A, Bordas JM, Castaneda B, et al. Predictive value of the variceal pressure response to continued pharmacological therapy in patients with cirrhosis and portal hypertension. Hepatology 2000;31:1061-7.